Boivin D B, Montplaisir J, Petit D, Lambert C, Lubin S
Centre d'étude du sommeil, Hôpital du Sacré-Coeur, Montréal, Québec, Canada.
Clin Neuropharmacol. 1993 Feb;16(1):46-53. doi: 10.1097/00002826-199302000-00005.
We studied the effects of modafinil, a putative central alpha-1 agonist, on the excessive daytime sleepiness (EDS) of 10 narcoleptic patients while using a double-blind design and objective measurements of vigilance. There were two treatment periods, in which either modafinil or placebo was used; each lasted four weeks and was preceded by a 2-week "run-in" period and separated by a 2-week "wash-out" period. The effects of treatment on EDS were evaluated by daily home questionnaires and a psychomotor performance test, the Four Choice Reaction Time Test (FCRTT). Modafinil reduced the daily number of sleep attacks significantly, and markedly improved performances during the FCRTT. Results of this study suggest that modafinil is effective in treating EDS in narcolepsy, and that noradrenergic mechanisms could be involved in the physiopathology of EDS in that disorder.
我们采用双盲设计和客观的警觉性测量方法，研究了莫达非尼（一种假定的中枢α-1激动剂）对10名发作性睡病患者日间过度嗜睡（EDS）的影响。有两个治疗阶段，分别使用莫达非尼或安慰剂；每个阶段持续四周，之前有一个为期2周的“导入”期，两个阶段之间有一个为期2周的“洗脱”期。通过每日家庭问卷和一项心理运动性能测试——四选反应时间测试（FCRTT）来评估治疗对EDS的影响。莫达非尼显著减少了每日睡眠发作的次数，并在FCRTT期间显著改善了表现。这项研究的结果表明，莫达非尼对治疗发作性睡病的EDS有效，并且去甲肾上腺素能机制可能参与了该疾病中EDS的病理生理过程。
